In Canada, approximately 75,500 are living with HIV and about 250,000 are living with hepatitis C (HCV).
Cannabis has been proven to be effective to relieve symptoms — including chronic pain management — related to many medical conditions.
The Cannabis Research Task Force brought together by the Canadian AIDS Society is expected to review the current state of research for the use of medical cannabis and develop a scope of work for evidence-based Canadian guidelines in such areas as treatment, contraindications, dosing, chronic pain, risk management and regulatory issues, among others.
As of July 6, 2017, the members of the Cannabis Research Task Force include:
|Shari Margolese||Community Research Consultant|
|Danial Schecter||MD and medical director, Canadian Cannabinoid Medical Clinic|
|Janet Yale||CEO, The Arthritis Society|
|Enrico Mandarino||Community Research Consultant and healthcare professional|
|Alan Bell||Family physician and clinical researcher|
|Caroline MacCallum||Internist / Clinical Instructor and Medical Director of Greenleaf Medical Clinic|
|Paul Daeninck||Medical oncologist|
|Jonathan Zaid||Executive Director, Canadians for Fair Access to Medical Marijuana|
|Lynne Belle-Isle||National Program Manager, CAS|
|Liz Christie||National Program Manager, CAS|
|Gary Lacasse||Executive Director, CAS|
|Hilary Black||Canopy Growth Corporation **Ex officio**|